Order Article Reprints

Stewart JP, Sandall CM, Parriott JE, Curran SM, McCulloh RJ, Ronning DR, Phillips JA, Schroeder R, Neel C, Lechtenberg KF, et al. Early-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant Staphylococcus aureus USA300. Pharmaceutics. 2024; 16(12):1621. https://doi.org/10.3390/pharmaceutics16121621

Stewart, Jason P., Caleb M. Sandall, Jacob E. Parriott, Stephen M. Curran, Russell J. McCulloh, Donald R. Ronning, Joy A. Phillips, Robin Schroeder, Christy Neel, Kelly F. Lechtenberg, and et al. 2024. "Early-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant Staphylococcus aureus USA300" Pharmaceutics 16, no. 12: 1621. https://doi.org/10.3390/pharmaceutics16121621

Stewart, J. P., Sandall, C. M., Parriott, J. E., Curran, S. M., McCulloh, R. J., Ronning, D. R., Phillips, J. A., Schroeder, R., Neel, C., Lechtenberg, K. F., Cohen, S. M., Alnouti, Y., Daria, S., Smith, D. D., & Vetro, J. A. (2024). Early-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant Staphylococcus aureus USA300. Pharmaceutics, 16(12), 1621. https://doi.org/10.3390/pharmaceutics16121621